Howard Wealth Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,746 shares of the company’s stock after selling 75 shares during the period. Howard Wealth Management LLC’s holdings in Johnson & Johnson were worth $620,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its holdings in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after buying an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares in the last quarter. Equitable Holdings Inc. grew its holdings in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after buying an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $145.60 on Monday. The stock has a market capitalization of $378.41 billion, a PE ratio of 10.81, a P/E/G ratio of 2.94 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The business has a fifty day moving average price of $158.90 and a two-hundred day moving average price of $161.94. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04.
Johnson & Johnson Dividend Announcement
Analyst Ratings Changes
JNJ has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Atlantic Securities raised their price target on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Finally, Raymond James reduced their target price on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a research note on Wednesday, October 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $169.19.
Check Out Our Latest Research Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Calculate Inflation Rate
- Is domestic travel back on track? Check out these companies
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 10/23 – 10/27
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Can casino stocks win big if economy slows?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
